Agents targeting proteins encoded by mutated EGFR, ALK, and ROS1 genes significantly improve the prognosis of advanced oncogene-driven non-small cell lung cancer (NSCLC) [1,2]. This evidence concerns the gene ALK and non-small cell lung carcinoma.